Key facts
- A Chinese biotech firm is developing a probiotic aimed at managing diabetes.
- The probiotic is described as 'smart,' suggesting advanced functionality.
- The company intends to pursue U.S. regulatory approval within the next two years.
A Chinese biotechnology company is working on a novel probiotic designed to help manage diabetes. The firm aims to bring this 'smart' probiotic to the U.S. market, with plans to submit for regulatory approval within the next two years. The development signifies a potential new avenue in the treatment of diabetes through advanced probiotic technology.